The largest database of trusted experimental protocols

3 protocols using granzyme b pe gb11

1

PBMC Cytotoxicity Assay against K562 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HLA-null K562 human chronic myelogenous leukemia cell line was purchased from ATCC (CCL-234) and cultured in cRPMI. Media was added every two days to maintain cell concentrations at 0.25×106 − 1.0×106 cells/mL. Cryopreserved PBMCs were thawed and pre-treated with IL-12 (1 ng/mL) and/or IL-18 (10 ng/mL) for 24 hours. K562 cells were labeled with Carboxyfluorescein succinimidyl ester (CFSE) according to the manufacturer’s instructions and then, co-cultured in a 96-well round bottom plate with 10:1, 5:1, and 2.5:1 PBMC effector to K562 target ratios. After 2.5 hours of incubation at 37°C and 5% CO2, cells were stained with Viability Mastermix. For effector phenotyping, cells were stained for surface [CD8-BV605 (RPA-T8), NKG2D-BV711 (1D11), and PD-1-AF647 (EH12.2H7) (all Biolegend)] and intracellular markers [Perforin-Pacific Blue (dG9; Biolegend), IFN-γ-PE-Cy7 (B27; BD Biosciences), Granzyme B-PE (GB11; BD Biosciences)] as described in section 2.2. Samples were collected on a BD Accuri C6 cytometer and analyzed using FlowJo software. Percent specific lysis was calculated by subtracting background lysis (Annexin V+PI+) in wells containing 0:1 PBMC to K562 cells from lysis in wells containing effector cells.
+ Open protocol
+ Expand
2

Comprehensive Immune Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies for flow cytometry and cell sorting were from Biolegend unless otherwise indicated. Antibodies used were: CD161 APC (HP-3G10), CD3 PE/Cy7 (UCHT1), CD3 APC/Cy7 (HIT3a), CD38 CF594 (HIT2, BD Biosciences), CD4 Alexa Fluor® 700 (RPA-T4), CD69 Pacific Blue™ (FN50), TCR γ/δ BV421™ (B1), Granzyme B PE (GB11, BD Biosciences), IFN-γ BV786 (4S.B3, BD Biosciences), TCR Vα7.2 BV605™ or PerCP/Cy5.5 (3C10), TNF BV650 (MAb11, BD Biosciences). Dead cells were excluded using LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies). Flow cytometry data was collected on BD LSRFortessa™ X20 or Invitrogen Attune NxT. Cell sorting was performed on BD FACSAria™ Fusion Cell Sorter or BD FACSAria™ III. Data was analyzed using FlowJo™ cell analysis software (FlowJo, LLC).
+ Open protocol
+ Expand
3

Phenotyping Naïve and Induced NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
To determine the purity and the surface markers of naïve and induced NK cells, the cells were adjusted to 1 × 106 cells/mL and stained with CD3-PerCP (SK7, cat # 347344), CD56-PE (B159, cat # 555516) or CD56-FITC (B159, cat # 562794), CD57-FITC (HNK-1, cat # 340706), NKG2D-APC (1D11, cat # 558071), KIR3DL1-APC (DX9, cat # 564103), KIR2DL2/3-PE (CH-L, cat # 559785), and KIR2DL1-PE (HP-3E4, cat # 556063) (all from BD Biosciences, San Jose, CA, USA) and NKG2A-PE (S19004C, cat # 375104; BioLegend) for 15 min at 23°C in the dark. The cells were washed twice with PBS and detected using a BD FACS Aria II flow cytometer (BD Biosciences) or ACEA NovoCyte D3000 flow cytometer (ACEA Biosciences Inc., San Diego, CA, USA). The data were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
CD16-FITC (NKP15, cat # 335035), interferon (IFN)-γ-PE (4S.B3, cat # 554552), granzyme B-PE (GB11, cat # 561142), perforin-PE (δG9, cat # 556437), and CD107a (H4A3, cat # 641581) assays (all from BD Biosciences) were carried out as previously described (27 (link), 28 (link)). Apoptosis was measured using the Annexin V-PE/7-AAD Apoptosis Detection Kit (eBioscience, San Diego, CA, USA), as per the manufacturer’s instructions. To analyze cell-cycle progression, induced NK cells were collected and labeled with propidium iodide.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!